There is no way that ACW can be cashed up till late 2025 without existing unlisted options being exercised. This is also a reason as to why a pullback/retracement will occur as well. They still need a sizeable amount of cash to fund the remaining AZ non Australian trial extension which is after the projected interim analysis mid 2025.
Ann: Positive Xanamem biomarker trial published in Jnl Alz Dis, page-54
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $206.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24515 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 82424 | 1 |
View Market Depth
| Last trade - 16.16pm 09/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |
Day chart unavailable